… The availability of prophylactic human papillomavirus (HPV) vaccines has provided …
vaccines have each been licensed in over 100 countries. By the beginning of 2012, HPV vaccine …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15 HPV
types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers. However…

… The licensed vaccines are safe and highly effective against the most common human
papillomavirus (HPV) types found in cervical and other anogenital cancers and are likely to prevent …

Human papillomavirus (HPV) vaccines are under investigation, but little is known about
attitudes regarding vaccination. The aims of this study were to identify attitudes about and …

… effect of a male vaccination program on female human papillomavirus (HPV) infection rates
and cervical cancer incidence, we needed to directly model the effect of vaccination on HPV …

… cancer, to define efficacy of HPV vaccines. While regulatory authorities of each country …
a useful endpoint in future vaccine efficacy studies. Indeed, if vaccines prove to be effective …

… human papillomavirus (HPV) vaccine was first introduced for females in the United States in
2006, vaccination policy has evolved as additional HPV vaccines … Vaccination coverage is …

Abstract In 2006, the US Food and Drug Administration (FDA) approved the first vaccine for …
®(quadrivalent human papillomavirus [HPV][types 6, 11, 16, and 18] recombinant vaccine, …

Human papillomavirus (HPV) infection causes virtually all cases of cervical cancer, the
second most common cause of death from cancer among women worldwide. This Review …